NCT05534672View on ClinicalTrials.gov

Placebo Controlled Study to Assess the Efficacy and Safety of Rapamycin in Drug Resistant Epilepsy Associated With Tuberous Sclerosis Complex

PHASE3RecruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

January 23, 2023

Primary Completion Date

June 30, 2027

Study Completion Date

June 30, 2027

Conditions
Tuberous Sclerosis Complex
Interventions
OTHER

Rapamycin

Rapamycin in liquid administered orally

OTHER

Placebo

Placebo in liquid administered orally

Trial Locations (2)

90-419

NOT_YET_RECRUITING

Medical University of Lodz, Lodz

04-730

RECRUITING

Children's Memorial Health Institute, Neurology and Epileptology, Warsaw

All Listed Sponsors
lead

Katarzyna Kotulska

OTHER